Musculoskeletal Disorders
Explore impacts on movement and quality of life
Research & Development
From molecule to medicine—closely connected to manufacturing
R&D supports TRB’s core therapeutic areas
R&D contributes to TRB’s core therapeutic areas in ophthalmology, rheumatology, and neurology. This work builds on key molecules including hyaluronic acid, diacerein, and GM1 ganglioside. A multidisciplinary team with expertise in biology, biotechnology, chemical engineering, nanoparticles, and pharmaceutical sciences supports these efforts. Together, they advance new products while continuously improving processes and sustainability, supported by modern equipment and a strong focus on quality and efficiency.
GM1 ganglioside
A complex lipid in nerve cell membranes, linked to signalling and cellular function
References
-
1. Wang S, Jiang Y, Yang A, et al. The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need. Aging and disease. 2024;16(5):2937–2952.
-
Mollà-Casanova S, Pedrero-Sánchez J, Inglés M, et al. Impact of Parkinson’s Disease on Functional Mobility at Different Stages. Frontiers in Aging Neuroscience. 2022;14:935841.
-
Pérez-Pérez J, García-López S, Valle TF, et al. Huntington Disease Health Related Quality of Life, Function and Well Being: The Patient’s Perspective. Neurology and Therapy. 2024;14:99–115.
-
Dueñas M, Ojeda B, Salazar A, et al. A review of chronic pain impact on patients, their social environment and the health care system. Journal of Pain Research. 2016;9:457–467.
-
Yanagisawa K. GM1 ganglioside and Alzheimer’s disease. Glycoconj J. 2015;32(3-4):105-12.
-
Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J Neurol Sci. 2013;324(1-2):140-8.